Javascript must be enabled to continue!
Pyridoxamine protects against mechanical defects in cardiac ageing in rats: studies on load dependence of myocardial relaxation
View through CrossRef
New Findings
What is the central question of this study?
This study aimed to investigate the hypothesis that pyridoxamine, one of the three natural forms of vitamin B6, can protect against myocardial relaxation of senescent animals by targeting arterial stiffening and contractile dysfunction of the left ventricle.
What is the main finding and its importance?
We found that treating the senescent rats with pyridoxamine for 5 months might improve myocardial relaxation rate, at least partly through its ability to enhance myocardial contractile performance, increase wave transit time and decrease wave reflection factor.
Our team demonstrated in the past that pyridoxamine attenuated arterial stiffening by targeting the pathogenic formation of glycated collagen cross‐links in aged rats. Herein, we examined whether pyridoxamine therapy can protect against mechanical defects in myocardial relaxation by improving arterial wave properties and cardiac contractile performance in senescent animals. Fifteen‐month‐old male Fisher 344 rats were treated daily with pyridoxamine (1 g l−1 in drinking water) for 5 months and compared with age‐matched untreated control animals (20 months old). Arterial wave properties were characterized by wave transit time (τw) and wave reflection factor (Rf). We measured the contractile status of the myocardium in an intact heart as the left ventricular (LV) end‐systolic elastance (Ees). Myocardial relaxation was described according to the time constant of the LV isovolumic pressure decay (τe). Pyridoxamine therapy prevented the age‐associated prolongation in LV τe and the diminished Ees in senescent rats. The drug also attenuated the age‐related augmentation in afterload imposed on the heart, as evidenced by the increased τw and decreased Rf. We found that the LV τe was significantly influenced by both the arterial τw and Rf (τe = 16.3902 + 8.3123 × Rf − 0.4739 × τw; r = 0.7048, P < 0.005). In the meantime, the LV τe and the LV Ees showed a significant inverse linear correlation (τe = 13.9807 − 0.0068 × Ees; r = 0.6451, P < 0.0005). All these findings suggested that long‐term treatment with pyridoxamine might ameliorate myocardial relaxation rate, at least partly through its ability to enhance myocardial contractile performance, increase wave transit time and decrease wave reflection factor in aged rats.
Title: Pyridoxamine protects against mechanical defects in cardiac ageing in rats: studies on load dependence of myocardial relaxation
Description:
New Findings
What is the central question of this study?
This study aimed to investigate the hypothesis that pyridoxamine, one of the three natural forms of vitamin B6, can protect against myocardial relaxation of senescent animals by targeting arterial stiffening and contractile dysfunction of the left ventricle.
What is the main finding and its importance?
We found that treating the senescent rats with pyridoxamine for 5 months might improve myocardial relaxation rate, at least partly through its ability to enhance myocardial contractile performance, increase wave transit time and decrease wave reflection factor.
Our team demonstrated in the past that pyridoxamine attenuated arterial stiffening by targeting the pathogenic formation of glycated collagen cross‐links in aged rats.
Herein, we examined whether pyridoxamine therapy can protect against mechanical defects in myocardial relaxation by improving arterial wave properties and cardiac contractile performance in senescent animals.
Fifteen‐month‐old male Fisher 344 rats were treated daily with pyridoxamine (1 g l−1 in drinking water) for 5 months and compared with age‐matched untreated control animals (20 months old).
Arterial wave properties were characterized by wave transit time (τw) and wave reflection factor (Rf).
We measured the contractile status of the myocardium in an intact heart as the left ventricular (LV) end‐systolic elastance (Ees).
Myocardial relaxation was described according to the time constant of the LV isovolumic pressure decay (τe).
Pyridoxamine therapy prevented the age‐associated prolongation in LV τe and the diminished Ees in senescent rats.
The drug also attenuated the age‐related augmentation in afterload imposed on the heart, as evidenced by the increased τw and decreased Rf.
We found that the LV τe was significantly influenced by both the arterial τw and Rf (τe = 16.
3902 + 8.
3123 × Rf − 0.
4739 × τw; r = 0.
7048, P < 0.
005).
In the meantime, the LV τe and the LV Ees showed a significant inverse linear correlation (τe = 13.
9807 − 0.
0068 × Ees; r = 0.
6451, P < 0.
0005).
All these findings suggested that long‐term treatment with pyridoxamine might ameliorate myocardial relaxation rate, at least partly through its ability to enhance myocardial contractile performance, increase wave transit time and decrease wave reflection factor in aged rats.
Related Results
Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease
Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease
Adherent neutrophils on vascular endothelium positively contribute to cell-cell aggregation and vaso-occlusion in sickle cell disease. In the present study, we demonstrated that py...
GW24-e3624 Myocardial regeneration in acute myocardial infarction rat model
GW24-e3624 Myocardial regeneration in acute myocardial infarction rat model
Objectives
To investigate the myocardial proliferation/regeneration and myocardial cell apoptosis during different time points and in different parts of the heart...
Animal Models of Aging Research
Animal Models of Aging Research
Ageing is associated with increased hypercoagulability, due to a slow rise of several coagulation factors, factor VIII, fibrinogen and thrombin-antithrombin complexes, markers of f...
Acetylcholinesterase inhibitor protects against cardiac ischaemia/reperfusion injury via enhancing mitophagy and rebalancing mitochondrial dynamics
Acetylcholinesterase inhibitor protects against cardiac ischaemia/reperfusion injury via enhancing mitophagy and rebalancing mitochondrial dynamics
Abstract
Background
Ischaemic heart disease is the most common cause of death globally. Although reperfusion therapy is essentia...
Ageing and cardiorespiratory response to hypoxia
Ageing and cardiorespiratory response to hypoxia
Key points
A previous study showed that an older age could be associated with a lower risk of...
e0071 Effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats
e0071 Effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats
Objective
To investigate effect of fluvastatin on myocardial interstitial fibrosis and cardiac function in diabetic rats.
...
Study of the mechanisms of protective effect of diazoxide on the myocardial mitochondrial functions after asphyxia in neonatal rats
Study of the mechanisms of protective effect of diazoxide on the myocardial mitochondrial functions after asphyxia in neonatal rats
Objectives
To explore the mechanisms of protective effects of diazoxide, a mitoKATP opener (KCO), on mitochondrial functions through detection of the opening of m...
Acute kidney injury during pregnancy leads to increased sFlt-1 and sEng and decreased renal T regulatory cells in pregnant rats with HELLP syndrome
Acute kidney injury during pregnancy leads to increased sFlt-1 and sEng and decreased renal T regulatory cells in pregnant rats with HELLP syndrome
Abstract
Background
The incidence of acute kidney injury (AKI) during pregnancy precedes a high maternal mortality rate o...

